Extended-schedule dose-dense temozolomide in refractory gliomas

This multicenter phase II study conducted by the Spanish Neuro-Oncology Group evaluated the activity of an extended, dose-dense temozolomide regimen in patients with temozolomide-refractory malignant glioma. Adult patients (at least 18 years of age) with WHO grade III or IV glioma and a Karnofsky Pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Berrocal, A., Perez Segura, P., Gil, M., Balaña, C., Garcia Lopez, J., Yaya, R., Rodríguez, J., Reynes, G., Gallego, O., Iglesias, L.
Formato: Texto
Lenguaje:English
Publicado: Springer US 2009
Materias:
Clinical Study - Patient Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808507/
https://www.ncbi.nlm.nih.gov/pubmed/19669096
http://dx.doi.org/10.1007/s11060-009-9980-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808507/
https://www.ncbi.nlm.nih.gov/pubmed/19669096
http://dx.doi.org/10.1007/s11060-009-9980-7

Ejemplares similares